open access

Vol 16, No 6 (2011)
Published online: 2011-11-01
Submitted: 2011-04-19
Get Citation

Hyperfractionated high-dose rate brachytherapy in the treatment of oral tongue cancer

Lubos Tuček, Jiri Petera, Igor Sirák, Milan Vošmik, Helena Doležalová, Simona Brokešová, Miroslav Hodek, Linda Kašaová, Petr Paluska
DOI: 10.1016/j.rpor.2011.07.001
·
Rep Pract Oncol Radiother 2011;16(6):243-247.

open access

Vol 16, No 6 (2011)
Published online: 2011-11-01
Submitted: 2011-04-19

Abstract

Background

Low-dose rate brachytherapy is a well established treatment modality of oral cancer. Data about high-dose rate (HDR) brachytherapy are still sparse with various fractionation schedules and heterogeneous results.

Aim

The aim of our retrospective study was to evaluate the results of HDR brachytherapy with doses of 3[[ce:hsp sp="0.25"/]]Gy twice daily.

Patients and methods

Twenty patients with squamous cell tongue cancer were treated in the years 2001–2009 by exclusive HDR BT 18[[ce:hsp sp="0.25"/]]×[[ce:hsp sp="0.25"/]]3[[ce:hsp sp="0.25"/]]Gy twice daily. The plastic tube technique was used. Median follow up was 47 months (7.8–118) since brachytherapy.

Results

The local and locoregional control was 85% and 68%, respectively. Bone necrosis developed in one case treated without mandibular shielding and soft tissue necrosis in 2 cases.

Conclusion

It can be concluded that HDR brachytherapy with 18[[ce:hsp sp="0.25"/]]×[[ce:hsp sp="0.25"/]]3[[ce:hsp sp="0.25"/]]Gy twice daily is safe with promising local control. The risk of nodal recurrences is substantial.

Abstract

Background

Low-dose rate brachytherapy is a well established treatment modality of oral cancer. Data about high-dose rate (HDR) brachytherapy are still sparse with various fractionation schedules and heterogeneous results.

Aim

The aim of our retrospective study was to evaluate the results of HDR brachytherapy with doses of 3[[ce:hsp sp="0.25"/]]Gy twice daily.

Patients and methods

Twenty patients with squamous cell tongue cancer were treated in the years 2001–2009 by exclusive HDR BT 18[[ce:hsp sp="0.25"/]]×[[ce:hsp sp="0.25"/]]3[[ce:hsp sp="0.25"/]]Gy twice daily. The plastic tube technique was used. Median follow up was 47 months (7.8–118) since brachytherapy.

Results

The local and locoregional control was 85% and 68%, respectively. Bone necrosis developed in one case treated without mandibular shielding and soft tissue necrosis in 2 cases.

Conclusion

It can be concluded that HDR brachytherapy with 18[[ce:hsp sp="0.25"/]]×[[ce:hsp sp="0.25"/]]3[[ce:hsp sp="0.25"/]]Gy twice daily is safe with promising local control. The risk of nodal recurrences is substantial.

Get Citation

Keywords

Oral cancer; High-dose rate brachytherapy

About this article
Title

Hyperfractionated high-dose rate brachytherapy in the treatment of oral tongue cancer

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 16, No 6 (2011)

Pages

243-247

Published online

2011-11-01

DOI

10.1016/j.rpor.2011.07.001

Bibliographic record

Rep Pract Oncol Radiother 2011;16(6):243-247.

Keywords

Oral cancer
High-dose rate brachytherapy

Authors

Lubos Tuček
Jiri Petera
Igor Sirák
Milan Vošmik
Helena Doležalová
Simona Brokešová
Miroslav Hodek
Linda Kašaová
Petr Paluska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl